Cited by 107

The DOI matches its Crossref record.

Epidemiology of drug-induced liver injury in China: a systematic analysis of the Chinese literature including 21,789 patients

Zhou, Yuan, Yang, Li, Liao, Zhongli, He, Xiaoyang, Zhou, Yuanyuan, Guo, Hong·2013·European Journal of Gastroenterology & Hepatology

Abstract

Background The epidemiology of drug-induced liver injury (DILI) in China has rarely been studied before. The aim of the present study was to determine the etiology of DILI in a Chinese population by reporting a systematic analysis of the Chinese literature published from 1994 to 2011. Methods A comprehensive database search of the Chinese literature was performed to obtain all the relevant studies. The data, including the drug names and patients' sex, age, clinical classification, and prognosis, were collected and analyzed. Results In this research, we found 279 studies including 24 112 patients. There were 265 studies that reported the sex of 21 789 patients, 11 787 men and 10 002 women. The therapeutics included (but were not limited to) tuberculostatics, complementary and alternative medicines (CAMs), antibiotics, NSAIDs, antineoplastics, central nervous system agents, antithyroid drugs, and immunomodulators. Of these drugs, tuberculostatics and CAMs were the most common etiologies of DILI in China. Conclusion DILI in China has a different etiology from that in Europe and USA. NSAIDs, which are the most common causes of DILI in western populations, are uncommon in China. Therefore, government, physicians, and patients should pay more attention to these drugs in DILI.

Overview

Integrity signals

Registry

Crossref · 10.1097/meg.0b013e32835f6889

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Valid epidemiology data of HILI are not available for the population in China.

    “In particular, valid epidemiology data of HILI are not available for the population; although, herbal TCMs are integral constituents of the Chinese health system.”
  • The respective cohorts in the 2019 Gastroenterology report were grouped under DILI and included liver injury cases caused by herbal TCM and herbal dietary supplements, not allowing for characterization of HILI epidemiology features.

    “However, the respective cohorts were grouped under the term of DILI, and represented still not only DILI but also liver injury cases caused by herbal TCM and herbal dietary supplements, representing two different product categories and again providing conditions similar to the shortcomings of the earlier study78 and not allowing for characterization of HILI epidemiology features.36”
  • An earlier vain epidemiology analysis was not RUCAM-based and used mixed cohorts of injury cases by drugs, herbs, or CAMs.

    “An earlier vain epidemiology analysis was not RUCAM-based and used mixed cohorts of injury cases by drugs, herbs, or CAMs.78”
  • Epidemiological data on DILI from medical centers across mainland China have not been available.

    “To date, epidemiological data on DILI from medical centers across mainland China have not been available.”
  • Females have been reported to have increased, unchanged, or even decreased incidence of DILI.

    “females have been reported to have increased, 8,26,27,31 unchanged, 9,30 or even decreased 12,21 incidence of DILI (Table 4).”

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 14

  1. Kaplowitz, 2001, Drug Saf, 24, 483, 10.2165/00002018-200124070-00001 · DOI
  2. Grant, 2012, Curr Opin Gastroenterol, 28, 198, 10.1097/MOG.0b013e3283528b5d · DOI
  3. Holt, 2010, Handb Exp Pharmacol, 196, 3, 10.1007/978-3-642-00663-0_1 · DOI
  4. Zhang, 2010, Zhongguo Zhong Yao Za Zhi, 35, 2199
  5. Xie, 2011, Diabetes Obes Metab, 13, 289, 10.1111/j.1463-1326.2010.01336.x · DOI
  6. Maartens, 2007, Lancet, 370, 2030, 10.1016/S0140-6736(07)61262-8 · DOI
  7. Wang, 2007, Lancet, 369, 691, 10.1016/S0140-6736(07)60316-X · DOI
  8. Ni, 2002, Med Care, 40, 353, 10.1097/00005650-200204000-00011 · DOI
  9. Wai, 2006, Singapore Med J, 47, 116
  10. Hu, 2012, Zhonghua Gan Zang Bing Za Zhi, 20, 173
  11. Bjornsson, 2010, Aliment Pharmacol Ther, 32, 3, 10.1111/j.1365-2036.2010.04320.x · DOI · Paper page
  12. Currie, 2011, J Health Econ, 30, 933, 10.1016/j.jhealeco.2011.05.009 · DOI
  13. Hussaini, 2007, Expert Opin Drug Saf, 6, 673, 10.1517/14740338.6.6.673 · DOI · Paper page
  14. Bjornsson, 2005, Hepatology, 42, 481, 10.1002/hep.20800 · DOI · Paper page

Cited by

Sorted by citations

Metadata

Authors
Zhou, Y., Yang, L., Liao, Z., He, X., Zhou, Y., & Guo, H.
Venue
European Journal of Gastroenterology & Hepatology
Published
2013-07
Volume
25
Issue
7
Pages
825-829
ISSN
0954-691X
Cited by
107
References
0
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review